Literature DB >> 32816723

Suboptimal Dosing of Fluconazole in Critically Ill Patients: Time To Rethink Dosing.

Eline W Muilwijk1,2, Dylan W de Lange3, Jeroen A Schouten4, Roeland E Wasmann1,2, Rob Ter Heine1, David M Burger1, Angela Colbers1, Pieter J Haas5, Paul E Verweij2,6, Peter Pickkers2,7, Roger J Brüggemann8,2.   

Abstract

Fluconazole is frequently used for the treatment of invasive Candida infections in critically ill patients. However, alterations in renal functions might influence fluconazole clearance. Therefore, our objective was to study the impact of renal function on the population pharmacokinetics of fluconazole in critically ill patients with various degrees of renal function or undergoing continuous renal replacement therapy (CRRT). This was an open-label, multicenter observational study. Critically ill patients receiving fluconazole were included. Baseline and clinical data were collected. At days 3 and 7 of enrollment, blood samples were drawn for pharmacokinetic curves. Additionally, daily trough samples were taken. A nonlinear mixed-effects model was built, followed by Monte Carlo simulations for assessment of exposure to various dosages of fluconazole. Nineteen patients were included with a median age of 64.4 (range, 23 to 81) years and median weight of 82.0 (range, 44.0 to 119.5) kg. A linear two-compartment model best described fluconazole pharmacokinetics and demonstrated higher clearance than expected in critically ill patients. Simulations showed that daily dosages of 600 mg and 800 mg are needed for intensive care unit (ICU) patients with normal renal function and patients on CRRT, respectively, to achieve the EUCAST-recommended target fAUC (area under the concentration-time curve for the free, unbound fraction of the drug)/MIC ratio of 100. In conclusion, fluconazole clearance is highly variable in ICU patients and is strongly dependent on renal function and CRRT. Trough concentrations correlated well with the AUC, opening up opportunities for tailored dosing using therapeutic drug monitoring. We recommend doses of 400 mg for patients with poor to moderate renal function, 600 mg for patients with adequate renal function, and 800 mg for patients treated with CRRT. (This study has been registered at ClinicalTrials.gov under identifier NCT02666716.).
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  azoles; fungal disease; intensive care unit; pharmacometrics; renal clearance; renal replacement therapy

Mesh:

Substances:

Year:  2020        PMID: 32816723      PMCID: PMC7508595          DOI: 10.1128/AAC.00984-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets.

Authors:  Kashyap Patel; Jason A Roberts; Jeffrey Lipman; Susan E Tett; Megan E Deldot; Carl M Kirkpatrick
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Population pharmacokinetics of fluconazole after administration of fosfluconazole and fluconazole in critically ill patients.

Authors:  T Aoyama; K Hirata; R Hirata; H Yamazaki; Y Yamamoto; H Hayashi; Y Matsumoto
Journal:  J Clin Pharm Ther       Date:  2011-08-24       Impact factor: 2.512

Review 3.  Allometric size: The scientific theory and extension to normal fat mass.

Authors:  Nick H G Holford; Brian J Anderson
Journal:  Eur J Pharm Sci       Date:  2017-05-25       Impact factor: 4.384

4.  Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients.

Authors:  C Csajka; L A Décosterd; T Buclin; J L Pagani; K Fattinger; J Bille; J Biollaz
Journal:  Eur J Clin Pharmacol       Date:  2001-12       Impact factor: 2.953

5.  A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients.

Authors:  R J M Brüggemann; W J F M Van Der Velden; C A J Knibbe; A Colbers; S Hol; D M Burger; J P Donnelly; N M A Blijlevens
Journal:  J Antimicrob Chemother       Date:  2014-12-03       Impact factor: 5.790

6.  Development of a sufficient design for estimation of fluconazole pharmacokinetics in people with HIV infection.

Authors:  Juliana F Roos; Carl M J Kirkpatrick; Susan E Tett; Andrew J McLachlan; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

7.  Pharmacokinetics of fluconazole in people with HIV infection: a population analysis.

Authors:  A J McLachlan; S E Tett
Journal:  Br J Clin Pharmacol       Date:  1996-04       Impact factor: 4.335

8.  Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods.

Authors:  D R Mould; R N Upton
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-04-17
  8 in total
  3 in total

1.  Might Confounding Factors Have an Effect on Suboptimal Dosing of Fluconazole in Critically Ill Patients?

Authors:  Emre Kara; Aygin Bayraktar Ekincioglu; Gokhan Metan
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

2.  Reply to Kara et al., "Might Confounding Factors Have an Effect on Suboptimal Dosing of Fluconazole in Critically Ill Patients?"

Authors:  E W Muilwijk; R J M Brüggemann
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

3.  Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis.

Authors:  Milo Gatti; Matteo Rinaldi; Giuseppe Ferraro; Alice Toschi; Natascia Caroccia; Federica Arbizzani; Emanuel Raschi; Elisabetta Poluzzi; Federico Pea; Pierluigi Viale; Maddalena Giannella
Journal:  Mycoses       Date:  2021-08-23       Impact factor: 4.931

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.